Contribution of Type 2 Diabetes to Major Adverse Cardiovascular Events (MACE) in a Long-term Observational Study with Different Stages of Atherosclerosis

Overview

Journal Sci Rep

Date 2025 Jan 22

PMID 39843486

Authors

Arthur Mader

Dario Haeberli

Barbara Larcher

Jorn F Dopheide

Christoph H Saely

Christine F Heinzle

Peter Amann

Marc Schindewolf

Andreas Festa

Heinz Drexel

Affiliations

Soon will be listed here.

Abstract

The impact of diabetes on incident cardiovascular disease in relation to the extent of atherosclerotic disease remains unclear. We aimed to investigate major adverse cardiovascular events (MACE) in patients with or without type 2 diabetes (T2DM) presenting with two extremes of atherosclerotic disease, those with angiographically documented minor coronary atherosclerotic lesions and those with symptomatic peripheral artery disease. We included 1238 patients from two prospective, long-term cohort studies. Patients underwent coronary angiography and/or sonography in order to assess the grade of atherosclerosis and were defined as having no signs of Atherosclerosis (n = 332; Group I), minor atherosclerosis (n = 425; Group II) and major atherosclerosis (n = 481; Group III). Cardiovascular events were recorded over a median follow-up period of 7.1 years (Q1 = 3.6 years, Q2 = 7.1 years, Q3 = 11.3 years), covering a total of 9533 patient years. We tested the hypothesis that T2DM infers the same relative risk increase irrespective of the atherosclerosis stage, considering 3-point MACE as the primary endpoint. Incident MACE was reported in 681 patients (51%). MACE occurred more frequently in patients with T2DM than in patients without T2DM (p < 0.001). Further, MACE occurred more frequently in group III (58.1%), than group II (34.1%) or group I (19.1%) (group I vs. group II vs. group III, p < 0.001). In a cox-regression-model, T2DM was a significant predictor of MACE in univariate analyses (HR = 2.43 [1.88-3.14], p < 0.001) and after multivariate adjustment for cardiovascular risk factors, as well as the different grades of atherosclerosis (HR = 1.37 [1.02-1.84], p = 0.034). Also, atherosclerosis grades predicted MACE (HR = 3.19 [2.75-3.70], p < 0.001) in univariate analyses, and also after multivariate adjustment for known cardiovascular risk factors, including T2DM (HR = 1.61 [1.31-1.98], p < 0.001). Finally, when testing for interactions between T2DM and stages of atherosclerosis on MACE we could not find any significant interaction (HR = 1.14 [0.86-1.52], p = 0.364). We conclude that T2DM infers an increased risk for MACE across anatomically and morphologically distinct stages of atherosclerosis.

References

Saely C, Aczel S, Marte T, Langer P, Drexel H . Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. Diabetologia. 2003; 47(1):145-6. DOI: 10.1007/s00125-003-1274-6. View

Sibley 3rd R, Reis S, MacFarlane J, Reddick M, Kalva S, Sutphin P . Noninvasive Physiologic Vascular Studies: A Guide to Diagnosing Peripheral Arterial Disease. Radiographics. 2016; 37(1):346-357. DOI: 10.1148/rg.2017160044. View

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A . 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal.... J Hypertens. 2023; 41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. View

Sprenger L, Mader A, Larcher B, Machler M, Vonbank A, Zanolin-Purin D . Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. BMJ Open Diabetes Res Care. 2021; 9(2). PMC: 8593703. DOI: 10.1136/bmjdrc-2021-002407. View

Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P . Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25):2387-97. DOI: 10.1056/NEJMoa1410489. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

Drexel H, Amann F, Rentsch K, Neuenschwander C, Luethy A, Khan S . Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol. 1992; 70(4):436-40. DOI: 10.1016/0002-9149(92)91186-8. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Dopheide J, Papac L, Schindewolf M, Baumgartner I, Drexel H . Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. J Clin Lipidol. 2018; 12(3):711-717. DOI: 10.1016/j.jacl.2018.02.013. View

10.

Badacz R, Kablak-Ziembicka A, Roslawiecka A, Rzeznik D, Baran J, Trystula M . The Maintained Glycemic Target Goal and Renal Function Are Associated with Cardiovascular and Renal Outcomes in Diabetic Patients Following Stent-Supported Angioplasty for Renovascular Atherosclerotic Disease. J Pers Med. 2022; 12(4). PMC: 9028557. DOI: 10.3390/jpm12040537. View

11.

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

12.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

13.

Raggi P, Cooil B, Ratti C, Callister T, Budoff M . Progression of coronary artery calcium and occurrence of myocardial infarction in patients with and without diabetes mellitus. Hypertension. 2005; 46(1):238-43. DOI: 10.1161/01.HYP.0000164575.16609.02. View

14.

Aday A, Matsushita K . Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021; 128(12):1818-1832. PMC: 8202714. DOI: 10.1161/CIRCRESAHA.121.318535. View

15.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

16.

Saely C, Sternbauer S, Vonbank A, Heinzle C, Zanolin-Purin D, Larcher B . Type 2 diabetes mellitus is a strong predictor of LDL cholesterol target achievement in patients with peripheral artery disease. J Diabetes Complications. 2020; 34(11):107692. DOI: 10.1016/j.jdiacomp.2020.107692. View

17.

Aboyans V, Ricco J, Bartelink M, Bjorck M, Brodmann M, Cohnert T . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,.... Eur Heart J. 2017; 39(9):763-816. DOI: 10.1093/eurheartj/ehx095. View

18.

Gerhard-Herman M, Gornik H, Barrett C, Barshes N, Corriere M, Drachman D . 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016; 135(12):e686-e725. PMC: 5479414. DOI: 10.1161/CIR.0000000000000470. View

19.

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

20.

Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W . Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care. 2004; 28(1):101-7. DOI: 10.2337/diacare.28.1.101. View